AUS
NZ
UK
CA
USA
IND
Highlights
ResMed CDI (ASX:RMD) operates within the healthcare sector and maintains a dual listing on the ASX and NYSE
RMD shares reflect a lower price-to-sales ratio compared to historical averages, supported by revenue growth
The company provides CPAP devices and healthcare SaaS solutions with global operational reach
ResMed CDI (ASX:RMD), part of the healthcare segment on the ASX 200, continues to capture attention within the medical technology landscape. The company is known for producing CPAP devices that support treatment for obstructive sleep apnea and operates across both the ASX and NYSE, with its primary listing in the US. As part of the S&P/ASX200 Healthcare Index (ASX:XHJ), ResMed’s footprint extends across over a hundred countries and includes extensive medical software services used in out-of-hospital settings.
With a focus on respiratory care and connected health solutions, RMD’s two core segments—Sleep and Respiratory Care and Software as a Service (SaaS)—highlight the integration of medical hardware and data platforms. The business’s approach centers on improving treatment efficiency while reducing broader system costs through technological applications.
ResMed’s Medical Devices Anchor Its Healthcare Position
The Sleep and Respiratory Care division underpins ResMed’s reputation in the global market. Its CPAP machines cater to patients experiencing nighttime respiratory issues and those requiring continuous respiratory support. These devices are used across a spectrum of needs—from simple overnight use to more critical, life-sustaining ventilation.
RMD also delivers a suite of medical accessories such as humidifiers and respiratory masks, each designed to complement its CPAP platforms. This integration supports consistent usage and enhances the operational scale of ResMed’s hardware-based solutions.
SaaS Division Expands ResMed’s Digital Capabilities
In parallel to its medical equipment offering, ResMed's SaaS division provides tools for healthcare providers engaged in home-based and durable medical equipment services. This digital platform enhances workflows and enables compliance documentation, logistics, and data monitoring. It is often utilized by providers managing patient treatment outside traditional hospital systems.
The SaaS unit emphasizes the importance of cloud connectivity and remote monitoring, enabling data-driven insights and treatment planning. It supports a shift toward value-based healthcare management by enabling informed decisions through software integration.
Valuation Metrics Reflect Historical Discount
According to recent data, the price-to-sales ratio of ResMed CDI (ASX:RMD) currently stands below its multi-year average. This comparison reveals that either the share price has declined or that revenue has increased over time. RMD’s revenue trend over the last few years has been on an upward trajectory, further influencing this valuation metric.
The metric is often used in broader assessments to evaluate how much the market is valuing a company relative to its sales. A lower multiple, in this context, signals a dislocation from previous valuation levels, which may prompt broader market attention to the stock.
Sustainable Sector Characteristics Attract Broader Market Interest
Healthcare remains one of the most resilient sectors within the ASX 200, historically known for steady performance during economic downturns. ResMed CDI (ASX:RMD), as part of this landscape, stands among those entities offering essential services that contribute to public health infrastructure. The provision of continuous care devices and digital tools enhances the healthcare delivery ecosystem, aligning with long-term trends in medical services and digital transformation.
Public interest in sustainable and essential service sectors has shown upward momentum, especially in areas where social utility aligns with financial metrics. As part of the healthcare category, RMD’s operations in respiratory treatment and cloud-based care delivery continue to place it at the core of out-of-hospital service expansion.
